Skip to main content
. 2020 Aug 25;72(10):1843–1849. doi: 10.1093/cid/ciaa1260

Figure 1.

Figure 1.

A, Risk mitigation approach adopted by the research team, demonstrating risk conferred by the study itself, the SARS-CoV-2 pandemic, controlled and uncontrolled comorbidities. B, Summary of risk mitigation strategy to be implemented by the study. Abbreviations: ATI, analytic treatment interruption; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.